Helsinn and Lyfebulb announce the Third Annual Patient-Driven Innovation Summit & Oncology Award

Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, and Lyfebulb, a patient empowerment platform that connects patients with industry to support user-driven innovation in chronic disease solutions, announced the launch of applications for their third annual Cancer Innovation Summit. Candidates are invited to submit applications where there is more information on criteria for eligibility. Submissions can be submitted until 17 November 2019.
The Summit is open to patient entrepreneurs building ground-breaking businesses to advance cancer prevention, diagnosis, management or care. Patient Entrepreneurs include patients with cancer, cancer survivors, or those with a close relative or cancer loved one. In order to better manage and improve the quality of life of cancer patients with respect, integrity, and quality, applicants for the competition must have established a company with impactful solutions.
Karin Hehenberger, Lyfebulb’s MD, Ph.D., Founder, and CEO, said that while cancer is a widespread disease, each patient and his or her family feel the impact of it very personally. They look forward to seeing the latest innovators personally affected by this disease and turning this experience and insights into much-needed solutions for our community.
The 2020 Lyfebulb-Helsinn Summit will take place at the Grimaldi Forum in Monaco on 29 and 30 January 2020, culminating in the announcement of the $25,000 Lyfebulb-Helsinn Award winner at the 14th Oncology Biennale in Monaco on 30 January. There will also be an additional $25,000 Squinto-LePera oncology award at that time.
Helsinn is a private pharmaceutical group with a wide portfolio of marketed products for cancer care and a robust pipeline for drug development. Helsinn has improved patients ‘ daily lives since 1976, guided by core family values of respect, integrity, and quality. The Group operates across pharmaceuticals, biotechnology, medical devices, and nutritional supplements and has expertise in research, development, manufacturing, and marketing of cancer, pain, inflammation, and gastroenterology therapeutic and supportive care products.
Headquartered in Lugano, Switzerland, the company has operating subsidiaries in Switzerland, Ireland, the U.S., Monaco, and China, as well as a global product presence in around 190 countries.